Why the study?
Interatrial shunting has emerged as a new therapy to decompress the left atrium in acute and chronic left heart failure, warranting an updated overview of its clinical perspective, challenges, and future directions.
Does interatrial shunting improve symptoms and clinical outcomes in patients with acute and chronic left heart failure?
Does interatrial shunting improve symptoms and clinical outcomes in patients with acute and chronic left heart failure?
Interatrial shunting is a promising and safe emerging therapy for left atrial decompression in refractory acute and chronic heart failure, though long-term randomized data are still needed.
Answers are grounded in this paper and cite their sources.
Interatrial shunting may benefit select refractory HF patients; leaves open efficacy confirmation in randomized trials.
The creation of an interatrial shunt has emerged as a new therapy to decompress the left atrium in patients with acute and chronic left heart failure (HF). Current data support the safety of this therapy, and promising preliminary efficacy results have been reported in patients who are refractory to optimal medical/device therapy. This article aims to provide an updated overview and clinical perspective on interatrial shunting for treating different HF conditions, and highlights the potential challenges and future directions of this therapy.
No takes yet. Share an insight, caveat, or question.
Guimarães et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: